Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.

Source: Analyst estimates for the quarter provided by FactSet.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...